Assertio Holdings and Garda Therapeutics Extend Tender Offer Commencement Deadline to May 4th for $125.1M Acquisition
ASRT has more than doubled off its 52-week low of $8.61.
Summary
Assertio Holdings and Garda Therapeutics have mutually agreed to extend the deadline for Garda's tender offer to acquire Assertio to May 4, 2026, as part of their previously announced $125.1 million merger agreement.
Key Events · M&A and Partnerships · ASRT
-
Tender Offer Deadline Extended
Assertio Holdings and Garda Therapeutics mutually agreed to extend the deadline for Garda's tender offer to acquire all outstanding shares of Assertio to May 4, 2026.
-
Acquisition Details Reaffirmed
The extension relates to the definitive agreement announced on April 8, 2026, where Garda will acquire Assertio for $18.00 per share in cash, totaling $125.1 million, plus a contingent value right.
-
Window-Shop Period Continues
The original merger agreement includes a 20-day "window-shop" period, allowing Assertio to engage with other parties for potentially superior bids, with a reduced breakup fee applicable if the agreement is terminated for a better offer during this period.
Analysis · ASRT · Life Sciences
This filing provides a formal update on the previously announced acquisition of Assertio Holdings by Garda Therapeutics. The mutual agreement to extend the tender offer commencement deadline to May 4, 2026, is a procedural step in the ongoing M&A process. While it delays the transaction slightly, it confirms that the acquisition is still moving forward. The original agreement, valued at $125.1 million or $18.00 per share in cash plus a contingent value right, remains in place. The mention of a 20-day "window-shop" period in the original agreement indicates that Assertio's board is still open to considering superior offers, which could introduce further developments.
At the time of this filing, ASRT was trading at $18.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.3M. The 52-week trading range was $8.61 to $20.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.